Dual-eligibles bill sets up another pharma fight over Medicare rebates

Democratic lawmakers in both houses of Congress are backing a new bill extending Medicaid-style rebates to low-income Medicare patients, saying the provision would save $141.2 billion. These so-called "dual eligibles" have been part of a tug-of-war over drug prices, with the pharma industry opposing any extension of Medicaid's steep rebates and healthcare-cost watchdogs advocating the move. Release | Report